AT1R gene rs389566 polymorphism contributes to MACCEs in hypertension patients

Jun-Yi Luo1,2, Guo-Li Du1,3, Yang-Min Hao3

  • 1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China.

PubMed

Insights

The AT1R gene rs389566 TT genotype is linked to a higher risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in hypertensive patients. This finding highlights the need for targeted prevention strategies in individuals with this genetic predisposition.

Area of Science:

  • Cardiovascular Genetics
  • Hypertension Research
  • Pharmacogenomics

Background:

  • Hypertension is a major risk factor for cardiovascular and cerebrovascular events.
  • Genetic polymorphisms, such as in the Angiotensin II Receptor Type 1 (AT1R) gene, may influence individual susceptibility to these events.
  • Understanding these associations can aid in personalized risk assessment and management.

Purpose of the Study:

  • To investigate the association between AT1R gene polymorphisms and major adverse cardiovascular and cerebrovascular events (MACCEs).
  • To assess this association in hypertensive patients in Xinjiang, with or without coronary artery disease (CAD).

Main Methods:

  • Genotyping of AT1R gene polymorphisms using SNPscan™ typing assays in 374 CAD patients and 341 non-CAD hypertensive individuals.
  • Follow-up assessments to record MACCEs.
  • Kaplan-Meier curves and Cox survival analyses to determine associations.

Main Results:

  • The AT1R gene rs389566 polymorphism was significantly associated with MACCEs.
  • The TT genotype of rs389566 showed a higher probability of MACCEs (75.2%) compared to AA + AT genotypes (24.8%, P=0.033).
  • Older age (OR=1.028) and the rs389566 TT genotype (OR=1.770) were identified as independent risk factors for MACCEs.

Conclusions:

  • The AT1R gene rs389566 TT genotype may predispose hypertensive patients to MACCEs.
  • Particular attention should be given to preventing MACCEs in hypertensive patients with CAD, especially the elderly with the rs389566 TT genotype.
  • Lifestyle modifications, blood pressure control, and awareness of genetic risk factors are crucial for reducing MACCEs.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
790
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
33
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
492
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
711
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K